Lifeline Biotechnologies Announced June 30, 2004 Sales Results and Anticipates Completion of Financial Audit
Wednesday July 21, 8:00 am ET

RENO, Nev.--(BUSINESS WIRE)--July 21, 2004--Lifeline Biotechnologies (OTCBB: LBTT - News) today announced sales results for the quarter ended June 30, 2004 of $114,209. The sales were composed of $46,485 for the Cancer Division (MastaScope) and $67,724 for the Orthopedic Division.
The Orthopedic Division's sales were made up of $23,058 to customers and the balance of $44,666 to the Lifeline distribution system. Jim Holmes, chairman of Lifeline Biotechnologies said, "of the company's 21 sales territories in the US, 15 have contract distributors and the remaining six are expected to have distributors appointed in the near term."

The sales of $114,209 for the June quarter compare to approximately $100,000 for the prior seven months. Holmes said, "This is a meaningful and significant increase and includes sales to customers for the Orthopedics Division. Also, and very importantly, the first sales of the MastaScope occurred in the second quarter with one unit sold in the US, one unit in Europe and one unit in Egypt."

Concerning the status of the company's audit, Holmes said that substantially all of the information requested by the Company's auditors has been provided to Malone & Bailey, CPAs "and we expect the audit's completion as soon as possible within the parameters of Malone & Bailey's schedule."

Lifeline Biotechnologies, Inc. is a company with innovative medical technologies committed to the improvement of the quality of life through exceptional health care systems. These technologies focus on prevention, early detection, diagnosis and quick recovery of a number of disease conditions. The company's two divisions, Orthopedics Instruments and Cancer Detection technologies, each deal with cutting edge innovation to assist practicing physicians to deliver quality medical care. The MastaScope(TM) is used in the early detection of cancer and other abnormalities of the breast. The MastaScope(TM) has completed development and has entered the marketplace in the US and internationally. The First Warning Systems for assisting in the early detection of breast cancer and the Ovarian Scope for assisting in the early detection of ovarian cancer are continuing to be developed by the company. The Orthopedic division is the exclusive distributor for the Arthronet Shaver Blades in the US, Canada and Mexico and also the exclusive distributor for the Inion bioabsorable screw for the US and Canadian markets. More information is available at the company's website: www.lbti.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In particular, when used in the preceding discussion, the words "believe", "expects", "projects", "forecasts", "intends", "will", "anticipated", "could", or "may", and similar conditional expressions are intended to identify forward-looking statements within the meaning of the act and are subject to the safe harbor created by the act. Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements that involve a number of risks and uncertainties.

--------------------------------------------------------------------------------
Contact:
Martin E. Janis & Company, Inc.
Bev Jedynak, 312-943-1100 ext. 12
b.jedynak-janispr@att.net

------------------
GLTA

Raja

RENO, Nev., Jul 22, 2004 (BUSINESS WIRE) -- Lifeline Biotechnologies Inc. (LBTT) today announced that it has retained Martin E. Janis & Company, Inc. of Chicago, as public relations counsel. Jim Holmes, CEO of Lifeline made the announcement, noting: "The Janis agency brings more than 54 years of experience in publicity placement, investor relations and political public relations to Lifeline. We believe that Lifeline Biotechnologies is at a point where it is time to get our story out into the general population. Martin E. Janis & Company, Inc. will assist us in this endeavor."

Martin E. Janis & Company, Inc., founded in 1950, is a full-service investor/public relations agency, offering its services to public as well as private corporations, trade associations, education and other institutions and government and political entities and individuals. In addition to a strong national presence in the publicity arena, the agency also provides complete investor relations services to its publicly held clients. More information on Martin E. Janis & Company, Inc. can be found at its website: http://www.janispr.com.

------------------
GLTA

Raja

------------------
GLTA

Raja

RENO, Nev., Jul 27, 2004 (BUSINESS WIRE) -- Jim Holmes, Chairman of the Board and Chief Financial Officer of Lifeline Biotechnologies (Pink: LBTT) today announced that Frank Clark has joined the company's board of directors and has been named Chief Executive Officer of the company. He replaces Holmes in this position. Holmes will now concentrate his efforts primarily on his role as chairman and chief financial officer.

"Mr. Clark brings an extensive background and many years of sales and marketing management experience. In addition to his executive roles at Johnson & Johnson, he has consulted for many early stage, developing and emerging health care companies. We believe that he will bring a much needed resource to Lifeline and can assist in implementing our strategies of market positioning and the entry of our medical products into the health care field," said Holmes.

Holmes went on to state: "For many years Lifeline has been focused on research and product development. One of these products, the MastaScope(TM), has completed development and sales have started. With the addition of Mr. Clark we can focus on a successful introduction of this product to the market."

Clark noted, "The market potential for the MastaScope(TM) and other products under development at Lifeline as well as enhanced outcomes in the early detection and diagnosis of various cancers can have a profound effect on women's health worldwide. The technology, commitment and dedication exhibited by the Lifeline team can lead to a successful outcome of our developmental efforts."

Holmes said that in a realignment of the Company's senior management Jonathan Reeves has been elevated to president and will handle the company's day-to-day operations. Bill Reeves, the company's founder will concentrate primarily on continuing the development of the company's flagship product, the First Warning System for assisting in the early detection of breast cancer. "Bill has been assisting in the development of the MastaScope(TM), handling operations and technical matters. These executive changes will enable Bill to focus on moving the First Warning System toward its market entry.

------------------
GLTA

Raja

RENO, Nev., Aug 17, 2004 (BUSINESS WIRE) -- Lifeline Biotechnologies, Inc. (PINK:LBTT) today announced that the company has retained Lopez, Blevins Bork & Associates, LLP, CPAs, Houston, Texas, to complete its previously announced audit. Mr. Carlos Lopez, partner in charge of the Lifeline audit, was formerly with the accounting firm of Malone-Bailey and recently left the Malone-Bailey firm to establish his own practice with this new firm. The company originally retained Malone and Bailey earlier this year and Mr. Lopez was the assigned auditor. As a result of his departure from the firm, the company's audit, which had been anticipated to be completed in June of this year, has been delayed.

"The completion of this audit is a major priority of the company at this time," stated Jim Holmes, Lifeline's CFO. "We are very comfortable with Carlos and he is extremely familiar with Lifeline and our activities. Although his decision to leave Malone-Bailey does create a delay, we are confident that our audit should be completed near term.

Lifeline Biotechnologies, Inc. is a company with innovative medical technologies committed to the improvement of the quality of life through exceptional health care systems. These technologies focus on prevention, early detection, diagnosis and quick recovery of a number of disease conditions. The company's two divisions, Orthopedics Instruments and Cancer Detection technologies, each deal with cutting edge innovation to assist practicing physicians to deliver quality medical care. The MastaScope(TM) is used in the early detection of cancer and other abnormalities of the breast. The MastaScope(TM) has completed development and has entered the marketplace in the US and internationally. The First Warning Systems for assisting in the early detection of breast cancer and the Ovarian Scope for assisting in the early detection of ovarian cancer are continuing to be developed by the company. The Orthopedic division is the exclusive distributor for the Arthronet Shaver Blades in the US, Canada and Mexico and also the exclusive distributor for the Inion bioabsorable screw for the US and Canadian markets. More information is available at the company's website: www.lbti.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In particular, when used in the preceding discussion, the words "believe", "experts", "projects", "forecasts", "intends", "will", "anticipated", "could", or "may", and similar conditional expressions are intended to identify forward-looking statements within the meaning of the act and are subject to the safe harbor created by the act. Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements that involve a number of risks and uncertainties.

SOURCE: Lifeline Biotechnologies, Inc.

RENO, Nev., Aug 20, 2004 (BUSINESS WIRE) -- Lifeline Biotechnologies Inc. (PINK: LBTT) today announced that the Trinion Meniscus Screw for use in knee cartilage repair, manufactured by Inion, of Finland and distributed in the U.S. by Lifeline, has received FDA clearance. The clearance allows Inion's Trinion screws to be marketed and sold in the US, complementing the company's Hexalon biodegradable cruciate ligament repair screw. These products are marketed to the sports medicine and orthopedic markets.

Trinion screws are used for the fixation of longitudinal vertical meniscus lesions, where the knee cartilage has torn. The benefits of the Trinion screw include a dual thread screw for optimal fixation with a headless design to allow complete insertion into the meniscus to avoid chondral lesion development. To aid surgeons, the screws are colored to allow improved visibility in arthroscopic procedures and are cannulated for increased ease of insertion.

FDA 510(k) clearance is awarded to medical device manufacturers prior to commercial distribution in the US. Trinion was awarded a CE-mark, the European equivalent of 510(k) clearance in July 2003. Lifeline Biotechnologies currently markets Inion's Haxalon product for anterior crucial ligament repair in the US.

Inion Ltd. is a Finnish company specializing in the development of biodegradable medical implants. Inion's core expertise and technology lies in the design and manufacture of innovative biodegradable polymer devices, such as plates, screws, pins and membranes. These implants are used to enhance the healing of skeletal injuries (bone and soft tissue), such as those caused by trauma or by reconstructive surgery. Inion uses expertise in polymer chemistry and surgical techniques to develop systems with strength and degradation profiles tailored for each surgical application.

I WISH THIS STOCK WAS NOT A PINK. MAYBE THE AUDIT WILL BRING THEM CURRENT AND OFF THE PINKS.

RENO, Nev., Aug 23, 2004 (BUSINESS WIRE) -- Lifeline Biotechnologies, Inc. (PINK: LBTT) today announced that it has signed an agreement with Vamstec, of Zagreb, Croatia that gives Vamstec exclusive rights to distribution the company's microendoscope product. Countries included in the agreement are Croatia, Slovenia, Bosnia and Herzegovina, Serbia, Montenegro, Macedonia, Bulgaria, Romania, Albania and Hungary.

This agreement marks the second European distribution agreement signed by the company for its MastaScope(TM) product line and includes minimum orders, which over the course of four years, are expected to generate $682,000 in sales (orders specifically without replacement Mastascopes).

"Although overall the Eastern European countries appear to be a small market in comparison to others, such as the U.S., we believe it is one that has good potential to grow beyond our expectations," said Carlo Micheletti, Lifeline's Director of International Sales and Marketing. He noted that the company was specifically conservative in negotiating minimum sales and that "we have reason to believe that these minimums will be easily surpassed during the four year period."

The MastaScope(TM), launched earlier this year, is a microendoscope that allows physicians opportunity for early stage visualization of breast abnormalities in patients with nipple discharge, while at the same time providing the specific ability to remove questionable tissue samples for biopsy.

Vamstec, founded 13 years ago, is a marketing and sales organization that services Croatia and other parts of the former Yugoslavia. The company also distributes a proprietary Clinical Image Management System (CIMS) to hospitals, physicians' offices and other clients in this geographic area.

RENO, Nev., Sep 7, 2004 (BUSINESS WIRE) -- Lifeline Biotechnologies, Inc. (PINK: LBTT) today announced that the company has entered into a four-year contract with International Medical Consulting Group (IMCG) of Dallas, Texas, for its Chinese company, Shanghai Science Medical Equipment, Ltd., to distribute Lifeline's proprietary MastaScope(TM) Mammary Ductoscopy System in the People's Republic of China.

Carlo Micheletti, Lifeline's Director of International Sales and Marketing, made the announcement. The distribution agreement requires IMCG to purchase a minimum of 100 systems during the next four years. "This is a great step forward for Lifeline Biotechnologies' growth and development," said Micheletti. "To be able to participate in and promote our product into this huge market has positioned Lifeline to be at the forefront of a growing market. The mammary ductoscopy procedure is used to assist surgeons in the early visualization and detection of breast abnormalities in patients with Pathological Nipple Discharge (PND) and other breast irregularities."

IMCG's Shanghi subsidiary has been in business for more than 20 years and is currently staffed by some 125 professional sales representatives, sub dealerships and a proficient support staff, covering all the major cities in the People's Republic of China. IMCG and SSME have the capability of providing educational support to breast cancer surgeons and other medical professionals in the mammary ductoscopy procedure. "We believe this ability can result in the potential to capture a high percentage of the emerging Chinese market," said Micheletti.